MA50786A - Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques - Google Patents
Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriquesInfo
- Publication number
- MA50786A MA50786A MA050786A MA50786A MA50786A MA 50786 A MA50786 A MA 50786A MA 050786 A MA050786 A MA 050786A MA 50786 A MA50786 A MA 50786A MA 50786 A MA50786 A MA 50786A
- Authority
- MA
- Morocco
- Prior art keywords
- neurological
- treatment
- combination product
- psychiatric disorders
- psychiatric
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000013066 combination product Substances 0.000 title 1
- 229940127555 combination product Drugs 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382718 | 2017-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50786A true MA50786A (fr) | 2022-04-27 |
Family
ID=60382132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050786A MA50786A (fr) | 2017-10-26 | 2018-10-26 | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11723894B2 (fr) |
| EP (1) | EP3713568A1 (fr) |
| MA (1) | MA50786A (fr) |
| WO (1) | WO2019081764A1 (fr) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3713568A1 (fr) | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| US20220071958A1 (en) * | 2019-02-22 | 2022-03-10 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
| EP4464377A3 (fr) * | 2019-02-22 | 2025-02-26 | GH Research Ireland Limited | Compositions comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) pour une utilisation dans le traitement de troubles mentaux |
| CN113993522A (zh) | 2019-04-17 | 2022-01-28 | 指南针探路者有限公司 | 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CA3145077A1 (fr) * | 2019-07-23 | 2021-01-28 | Caamtech, Inc. | Compositions contenant des composes a base de secretions de crapaud |
| CA3147679A1 (fr) * | 2019-08-13 | 2021-02-18 | Scott Thompson | Methodes de traitement de troubles psychologiques et cerebraux |
| PT3873883T (pt) * | 2019-11-07 | 2023-03-24 | Small Pharma Ltd | Método de síntese |
| CA3165903A1 (fr) | 2019-12-26 | 2021-07-01 | Gilgamesh Pharmaceuticals, Inc. | Derives arylcyclohexylamine et leur utilisation dans le traitement de troubles psychiatriques |
| KR20220137083A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| PL4084791T3 (pl) * | 2020-02-18 | 2025-04-22 | Gilgamesh Pharmaceuticals, Inc. | Specyficzne tryptaminy do zastosowania w leczeniu zaburzeń nastroju |
| EP3868364A1 (fr) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aérosol comrpenant 5-methoxy-n,n-dimethyltryptamine |
| BR112022017097A2 (pt) * | 2020-02-28 | 2022-11-16 | Univ Basel | Composição e uso da composição |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| PH12022553135A1 (en) | 2020-05-19 | 2024-03-04 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP3902541B1 (fr) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Compositions thérapeutiques comprenant des composés de n,n-dimethyltryptamine deutérés ou partiellement deutérés |
| US12042564B2 (en) * | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| CA3179161C (fr) * | 2020-06-02 | 2023-10-31 | Small Pharma Ltd | Compositions therapeutiques comprenant des composes de n,n-dimethyl tryptamine deuteree ou partiellement deuteree |
| EP4595962A3 (fr) | 2020-06-12 | 2025-10-22 | Beckley Psytech Limited | Composition pharmaceutique |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| AU2021334933B2 (en) * | 2020-08-28 | 2023-01-19 | Cybin Uk Ltd | Injectable formulation |
| AU2021337466A1 (en) | 2020-09-01 | 2023-03-30 | Enveric Biosciences Canada Inc. | Halogenated psilocybin derivatives and methods of using |
| WO2022047580A1 (fr) * | 2020-09-01 | 2022-03-10 | Magicmed Industries Inc. | Dérivés de psilocybine hydroxylés et leurs procédés d'utilisation |
| CA3194558A1 (fr) * | 2020-10-02 | 2022-04-07 | Brett J. GREENE | Methodes d'administration de medicaments psychedeliques par inhalation et systemes de mise en ?uvre des methodes |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| WO2022117640A1 (fr) * | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Formulations inhalables |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| KR20230109765A (ko) * | 2020-12-09 | 2023-07-20 | 캄테크, 인크. | 다이알킬 트립타민 및 이의 치료적 용도 |
| EP4155306A1 (fr) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Analogue neuroactif d'ergoline |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| CA3214120A1 (fr) * | 2021-03-30 | 2022-10-06 | Wilfred Jefferies | Utilisation de psychedeliques pour traiter la demence |
| TW202304423A (zh) * | 2021-04-01 | 2023-02-01 | 美商泰仁生物科學公司 | 與致幻劑及血清素受體調節劑相關之方法及組合物 |
| BR112023022195A2 (pt) * | 2021-04-26 | 2024-01-16 | Atai Therapeutics Inc | Novas composições e métodos de n,n-dimetiltriptamina |
| US20230136824A1 (en) | 2021-04-26 | 2023-05-04 | ATAI Life Sciences AG | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
| JP2024517194A (ja) * | 2021-05-03 | 2024-04-19 | マインド メディシン， インコーポレイテッド | サイケデリック薬の用量を漸増する方法 |
| WO2022235531A1 (fr) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Troubles du mouvement |
| CA3219041A1 (fr) | 2021-05-24 | 2022-12-01 | Canna-Chemistries Llc | Sels cristallins de psilocine |
| CN117642383A (zh) * | 2021-05-24 | 2024-03-01 | 卡纳-化学有限责任公司 | 二甲-4-羟色胺的结晶盐 |
| MX2023013928A (es) | 2021-05-25 | 2023-12-08 | Atai Therapeutics Inc | Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina. |
| JP2024522174A (ja) | 2021-06-09 | 2024-06-11 | アタイ セラピューティクス， インコーポレイテッド | ジメチルトリプタミンの新規プロドラッグおよびコンジュゲート |
| TW202317545A (zh) | 2021-07-07 | 2023-05-01 | 美商泰仁生物科學公司 | N,n-二甲基色胺及相關致幻劑及其用途 |
| CA3230779A1 (fr) | 2021-09-03 | 2023-03-09 | Paul Daley | Allyl tryptamines asymetriques |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (fr) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Spray nasal à base de diméthyltriptamine pour le traitement personnalisé des troubles neurologiques et psychiatriques |
| CA3237988A1 (fr) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybine et o-acetylpsilocine, leurs sels et formes a l'etat solide |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023111544A2 (fr) * | 2021-12-13 | 2023-06-22 | Beckley Psytech Limited | Sel de benzoate de 5-méthoxy-n,n-diméthyltryptamine |
| US12012381B2 (en) | 2021-12-30 | 2024-06-18 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| SE2250051A1 (en) | 2022-01-20 | 2023-07-21 | Amidea Sweden Ab | New pharmaceutical composition and uses thereof |
| EP4486448A1 (fr) | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-cristaux ou sels comprenant de la psilocine |
| EP4499074A1 (fr) * | 2022-03-27 | 2025-02-05 | GH Research Ireland Limited | 5-meo-dtm pour le traitement d'un trouble bipolaire |
| AU2023244452A1 (en) * | 2022-03-27 | 2024-11-07 | GH Research Ireland Limited | Treatment of cognitive dysfunction |
| US20240000795A1 (en) * | 2022-06-30 | 2024-01-04 | Terran Biosciences Inc. | Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| EP4584247A2 (fr) * | 2022-09-06 | 2025-07-16 | ATAI Therapeutics, Inc. | Amines cycliques et alkyliques substituées par un hétéroatome en tant qu'activateurs de récepteurs de la sérotonine |
| CN115813917A (zh) * | 2022-11-02 | 2023-03-21 | 张樟进 | 一种具有快速改善认知功能的化合物及应用 |
| WO2024097868A1 (fr) * | 2022-11-02 | 2024-05-10 | Caamtech, Inc. | Relations structure-activité pour psilocybine, baéocystine, aerugincine et analogues associés pour produire des effets pharmacologiques |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12157722B1 (en) | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| WO2025052388A1 (fr) * | 2023-09-07 | 2025-03-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composés psychédéliques, leurs procédés de préparation et leurs utilisations |
| WO2025111597A1 (fr) * | 2023-11-22 | 2025-05-30 | Gilgamesh Pharmaceuticals, Inc. | Traitement de patients atteints de troubles de l'humeur à l'aide de n-éthyl-2-(5-fluoro-1h-indol-3-yl)-n-méthyléthan-1-amine ou d'un sel pharmaceutiquement acceptable de celle-ci |
| WO2025137730A1 (fr) * | 2023-12-22 | 2025-06-26 | Alexander Shulgin Research Institute, Inc. | Tryptamines n-substituées et lysergamides n-substitués et leur utilisation comme agents thérapeutiques |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| US6579899B1 (en) * | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
| CA2529857A1 (fr) | 2002-07-30 | 2004-02-05 | Peter Migaly | Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques |
| CN101677971A (zh) | 2007-03-19 | 2010-03-24 | 阿卡蒂亚药品公司 | 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合 |
| US8986677B2 (en) | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| JP2016513734A (ja) * | 2013-03-15 | 2016-05-16 | エーエルエス マウンテン リミテッド ライアビリティ カンパニー | Ａｍｐｋ活性化剤及びセロトニン作動薬を含む医薬組成物並びにそれらの使用方法 |
| NL2018190B1 (en) | 2017-01-18 | 2018-07-26 | Procare Beheer B V | Psilocybin or psilocin in combination with cannabinoid |
| EP3713568A1 (fr) | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| US11045454B2 (en) | 2018-12-06 | 2021-06-29 | Palo Alto Investors LP | Methods of treating food allergy conditions |
| CA3147679A1 (fr) | 2019-08-13 | 2021-02-18 | Scott Thompson | Methodes de traitement de troubles psychologiques et cerebraux |
-
2018
- 2018-10-26 EP EP18796407.7A patent/EP3713568A1/fr active Pending
- 2018-10-26 MA MA050786A patent/MA50786A/fr unknown
- 2018-10-26 US US16/958,226 patent/US11723894B2/en active Active
- 2018-10-26 WO PCT/EP2018/079503 patent/WO2019081764A1/fr not_active Ceased
-
2023
- 2023-06-21 US US18/339,174 patent/US20240165079A1/en not_active Abandoned
- 2023-06-21 US US18/339,172 patent/US20230330063A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20230330063A1 (en) | 2023-10-19 |
| US20240165079A1 (en) | 2024-05-23 |
| WO2019081764A1 (fr) | 2019-05-02 |
| US11723894B2 (en) | 2023-08-15 |
| EP3713568A1 (fr) | 2020-09-30 |
| US20200397752A1 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50786A (fr) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3600281A4 (fr) | Traitement d'association pour le traitement ou la prévention de tumeurs | |
| EP3870272A4 (fr) | Stimulation nerveuse pour le traitement de la migraine et d'autres états de céphalée | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| EP3180022A4 (fr) | Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase | |
| EP3765611A4 (fr) | Oligonucléotides ciblant la pcsk9 pour le traitement de l'hypercholestérolémie et d'états apparentés | |
| MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| MA47608A (fr) | Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3445352A4 (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| EP3541408A4 (fr) | Compositions et méthodes pour le traitement de l'angiogenèse aberrante | |
| MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| EP3644983A4 (fr) | Compositions et méthodes de traitement ou de prévention d'affections pulmonaires fibreuses | |
| EP3723768A4 (fr) | Composés pour le traitement et la prévention de pathologies médiées par l'histone extracellulaire | |
| EP3405201A4 (fr) | Carbonate de calcium amorphe stabilisé pour le traitement de maladies ou d'affections neurologiques ou musculaires et l'infertilité | |
| EP3801478A4 (fr) | Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie | |
| WO2017177024A8 (fr) | Méthodes de traitement de troubles oculaires | |
| EP3554626A4 (fr) | Méthodes et dispositifs destinés au traitement de troubles d'origine vasculaire | |
| EP3529234A4 (fr) | Composés, procédé d'obtention des composés, composition pharmaceutique, utilisation des composés et procédé de traitement de troubles psychiatriques et/ou de troubles du sommeil | |
| EP3654961A4 (fr) | Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine | |
| EP3398614A4 (fr) | Agent pour la prévention et/ou le traitement de la maladie d'alzheimer | |
| EP3710015A4 (fr) | Utilisation d'agents srsf3 pour le traitement et/ou la prévention d'affections neurologiques, du cancer, d'infections bactériennes ou d'infections virales | |
| EP3506927A4 (fr) | Compositions de reeline pour le traitement des troubles neurologiques |